Introduction
Psoriasis is a potentially debilitating disease, which due to chronic inflammation, may have effects on other organ systems in addition to the skin, resulting in increased risk of cardiovascular, liver and renal disease (1) (2) (3) (4) . Analyses of immune cells circulating in the blood of patients with psoriasis have revealed unique gene signatures compared with healthy controls, providing evidence of the systemic nature of the disease (5) . Abnormal immune responses in the skin are involved in the pathophysiology of psoriasis, resulting in inflammation and increased epidermal proliferation. Therapies that block T-cell proliferation or specific therapies that block cytokines, including tumor necrosis factor (TNF), interleukin (IL)-17, IL-12 and IL-23, have been demonstrated to be effective in the treatment of psoriasis patients. The various cytokines involved in this aberrant immune-mediated disease are produced by T cells, myeloid cells including dendritic cells and macrophages, and epidermal keratinocytes. Although it may appear counterintuitive to have immunoregulatory cells in autoimmune and inflammatory diseases, chronic inflammatory responses initiate an increase of regulatory immune cells to attempt to downregulate the response. These immunoregulatory cells may produce various molecules that alter the inflammatory milieu (6) .
Myeloid-derived suppressor cells (MDSCs) , are a population of immature myeloid cells with an immune regulatory role. Myeloid-derived suppressor cells originate from common myeloid progenitors in the bone marrow; however, under inflammatory conditions an aberrant sustained myelopoiesis may result in the accumulation of immature myeloid cells. These myeloid cells then deviate from the standard path of differentiation depending on the inflammatory milieu. This deviation may lead to the activation of immunoregulatory pathways, including activation of the enzymes arginase 1 and nitric oxide synthase 2, and production of reactive oxygen species. These metabolic pathways have been demonstrated to affect every arm of the immune system (7, 8) . MDSC suppress T-cell proliferation (9), inhibit natural killer (NK) cell cytotoxicity (10), modulate macrophage polarization (11, 12) and induce the development of regulatory T cells (13) . MDSCs have been demonstrated to modulate the immune response to various diseases, including numerous types of cancer (14) (15) (16) (17) (18) (19) , inflammatory bowel disease (IBD) (20) , traumatic stress (21), burns (22) , infections (23, 24) and transplantation (25) . In addition, a recent study has indicated that MDSCs are elevated in patients with psoriasis (26) . MDSCs under certain conditions may differentiate into endothelial cells, macrophages, dendritic cells or neutrophils (27, 28 The aim of the present study was to assess circulating MDSC levels in the peripheral blood of patients with psoriasis relative to healthy controls. Furthermore, the production of cytokines, chemokines and matrix metalloproteinases (MMPs) by MDSCs, which may contribute to the inflammatory state, was investigated.
Materials and methods
Blood donors and sample preparation. A protocol for informed consent was developed with the support of the Clinical & Translational Science Institute at the University of Pittsburgh (Pittsburgh, PA, USA), and the present study was approved by the Internal Review Board of the University of Pittsburgh. Healthy controls or patients with psoriasis covering >10% body surface area, and who did not have viral hepatitis, human immunodeficiency virus or an autoimmune disease, and were not on any immune-modulating systemic medications (for example, prednisone, biologics, methotrexate, cyclosporine or retinoids) were enrolled in the present study following the receipt of signed informed consent (n=11 healthy controls; n=15 patients with psoriasis). The average age of patients was 38 years for healthy controls and 48 years for psoriasis patients, which was not significantly different (P= 0.080). The average body mass index of patients was 25 for healthy controls and 26 for psoriasis patients, which was not significantly different (P=0.890). The healthy control group consisted of 5 males and 6 females, and the psoriasis group consisted of 5 males and 10 females. Blood (up to 20 ml per draw) was collected in heparinized tubes (BD Biosciences, San Jose, CA, USA) and processed within 4 h by diluting blood with phosphate-buffered saline (PBS) to 40 ml. Diluted blood was underlaid with 10 ml Ficoll-Paque Premium 1.084 density gradient medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Samples were centrifuged at 300 x g, at room temperature and without brake for 20 min. The peripheral blood mononuclear cell (PBMC)-containing interphase layer was removed, washed with PBS, and resuspended in Recovery™ cell culture freezing medium (Invitrogen; Thermo Fisher Scientific, Inc.) and aliquoted into cryovials. Samples were placed into a -80˚C freezer in a Mr. Frosty container (Thermo Fisher Scientific, Inc.) to ensure controlled cooling at 1˚C/minute. Samples were transferred to liquid nitrogen for storage after 1 week. Prior to analysis, stored samples were thawed rapidly in a 37˚C water bath.
Flow cytometry. Cells (1x10 6 per tube) were Fc blocked for 5 min, using 2 µl anti-CD32 (catalog no. 555447; BD Biosciences), and the following antibodies were added in magnetic-activated cell sorting (MACS) separation buffer (Miltenyi Biotec, Inc., Auburn, CA, USA): Anti-HLA-DR-phycoerythrin (PE; G46-6; catalog no. 555812), anti-CD14-PacificBlue (M5E2; catalog no. 558121), anti-CD15-allophycocyanin (APC; HI98; catalog no. 551376), anti-CD3-fluorescein isothiocyanate (FITC; SK7; catalog no. 349201), anti-CD56-FITC (NCAM16.2; catalog no. 340410), anti-CD20-FITC (L27; catalog no. 347673), anti-CD19-FITC (SJ25C1; catalog no. 340719), anti-CD4-PacificBlue (RPA-T4; catalog no. 561844) and anti-CD8-BV786 (RPA-T8; catalog no. 563823), purchased from BD Biosciences. Antibodies were incubated for 30 min at 4˚C at concentrations indicated by the manufacturer. Cells were subsequently fixed with 1% paraformaldehyde in MACS separation buffer, and samples were analyzed on an LSR II (BD Biosciences). One aliquoted and cryopreserved healthy control blood sample served as an interexperimental control in serial flow cytometric analyses. Granulocytic MDSCs were defined as HLA-DR lo/-CD15 + , and monocytic MDSCs as HLA-DR lo/-CD14 + , as described previously (29) .
Suppression assay and MDSC purification. Patient samples were thawed and 3x10 6 PBMCs were removed and labeled with 1 µmol/l 5-(and 6) carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen; Thermo Fisher Scientific, Inc.) for 15 min at 37˚C, according to the manufacturer's protocol. The remaining thawed unlabeled PBMCs were resuspended in MACS separation buffer and labeled with anti-HLA-DR microbeads (Miltenyi Biotec, Inc.). MACS was then performed on LS columns (Miltenyi Biotec, Inc.) according to the manufacturer's protocol. HLA-DR depleted cells were then labeled with anti-CD14 microbeads and separated on columns to obtain HLA-DR lo/-CD14 + cells. Flow through cells (HLA-DR lo/-CD14 -cells) were then labeled with anti-CD3 microbeads (Miltenyi Biotec, Inc.) and separated to obtain CD3 + cells. Cells were resuspended in AIM-V medium (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 2 mM Glutamax (Invitrogen; Thermo Fisher Scientific, Inc.), 50 U/ml penicillin/50 µg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) and 500 U/ml IL-2 (BD Biosciences). Culture plates (96-well) were precoated overnight with 50 µl/well 1 µg/ml anti-CD3 (BD Biosciences). CFSE-labeled PBMCs were plated at 2x10 5 cells/well and MDSCs were added at various ratios. For stimulation, 2.5 µg/ml anti-CD28 (BD Biosciences) was added to culture wells in addition to the plate bound anti-CD3. Final volume was 300 µl/well. On day 6 of culture, cells were harvested, labeled with anti-CD4 and anti-CD8 antibodies as aforementioned, and CFSE dilution was analyzed by flow cytometry.
Cytokine analysis. Cells were purified and cultured as aforementioned (2x10 5 /well in 96-well plates) for 2 days, and then supernatants were collected and stored until analysis. Supernatants were analyzed by Luminex bead-based technology at the Luminex Core Facility at the University of Pittsburgh Cancer Institute (Pittsburgh, PA, USA).
Statistical analysis. Data are expressed as mean ± standard error. Groups were compared using two-tailed t-tests. P<0.05 was considered to indicate a statistically significant difference.
Results

MDSC levels in the circulation of patients with psoriasis.
PBMCs were isolated from patients with psoriasis and healthy controls. There were no statistically significant differences in age or body mass index between the two groups. Flow cytometry was performed to analyze MDSC levels within the PBMCs by gating on non-lymphocytes, cells negative for T, B, and NK cell markers (CD3  -CD19  -CD20  -CD56   -) , and analyzing CD14, CD15 and HLA-DR (Fig. 1A) . A significant increase was observed in HLA-DR lo/-CD14 + cells (P=0.005), considered to be monocytic MDSCs, and HLA-DR lo / -CD15 + cells (P=0.004), considered to be granulocytic MDSCs, in patients with psoriasis compared with healthy controls (Fig. 1B and C) . There was no significant difference in the percentage of mature monocytes (HLA-DR + CD14 + ) between the two groups (P=0.351) (Fig. 1D) .
Circulating MDSCs are properly identified by phenotype and function.
MDSCs are defined by their suppression of T-lymphocyte proliferation in response to various stimuli in vitro, in addition to phenotypic markers. As granulocytic MDSCs exist in relatively low numbers, are difficult to isolate and have been demonstrated to lose their regulatory function following cryopreservation (30) , the regulatory function of HLA-DR lo/-CD14 + cells was analyzed. MDSCs from the PBMCs of patients with psoriasis were isolated, and co-cultured at various ratios with autologous CFSE-labeled PBMCs activated with anti-CD3 and -CD28. CFSE dilution in activated CD4 + and CD8 + T cells was analyzed following 6 days of culture, and a representative experiment revealed that CD4 + and CD8 + T-cell proliferation was suppressed by MDSCs in a dose-dependent manner (Fig. 1E) . At a 1:1 PBMC to MDSC ratio, CD8 + and CD4 + T-cell proliferation is greatly reduced compared with T cell proliferation in the absence of MDSC or in the presence of low numbers of MDSC (ratio 1:0.13). This in vitro regulatory function indicates that the population identified in the present study is that described previously as MDSCs (29) . (Fig. 2 and data not shown). MDSCs cultured under various in vitro conditions may produce these molecules; however, the aim of the present study was to determine which molecules are produced at baseline by circulating MDSCs.
Discussion
MDSCs have been identified in various skin diseases, including melanoma (15) , squamous cell carcinoma (31), radiation and burn injury (32) , contact dermatitis (33) , atopic dermatitis (6, 34) , and a recent study reported elevated levels of MDSCs in patients with psoriasis (26) . The aim of the present study was to determine if MDSCs are elevated in the circulation of patients with psoriasis. The results demonstrated that granulocytic and monocytic MDSC subtypes were significantly increased in patients with psoriasis compared with healthy controls. MDSCs were identified by phenotype (HLA-DR lo/-CD15 + for granulocytic MDSC and HLA-DR lo/-CD14 + for monocytic MDSC) and function (suppression of CD4 + and CD8 + T cells). This suppression of T cells may initially appear counterintuitive, as psoriasis is associated with overactive T cells, and therapeutic strategies for patients with psoriasis may involve suppressing T cell activity. However, in IBD, a disease that may similarly be treated through T-cell suppression, MDSCs were demonstrated to be elevated, but markedly increased levels were required in vivo to successfully suppress the disease (20, 35, 36) . In contrast to in vitro studies, in vivo circulating MDSCs may not successfully interact with pathogenic T cells, they may differentiate into other cell types, or they may suppress only certain T-cell subtypes. A recent study, which demonstrated elevated levels of MDSCs in patients with psoriasis, also demonstrated that MDSCs from healthy controls and psoriatic patients induced conversion of T effector cells to T regulatory cells (26) . However, MDSCs from patients with psoriasis induced T regulatory cells that were markedly less suppressive, and thus less able to regulate the inflammatory response.
The present study hypothesized that MDSCs in patients with psoriasis may contribute to the inflammatory state, and have additional roles to the regulation of T-cell activity. Previous reports have revealed that myeloid cells from the peripheral blood of patients with psoriasis produce increased levels of IL-1β, IL-8, TNF-α and IL-6 compared with healthy controls (37, 38) . In addition, blood monocytes from patients with psoriasis have unique gene signatures that contribute to the chronic inflammatory state (5) . In the present study, MDSCs from patients with psoriasis were demonstrated to produce MMP9, MMP1, IL-8, GRO, and MCP-1. These molecules may contribute to recruitment of other inflammatory cells, including neutrophils and monocytes. Various cytokines and molecules are produced by myeloid lineage cells; this is consistent with the production by MDSC of molecules that may be involved in sustaining MDSC function and accumulation in a feedback mechanism, and in addition may contribute to the recruitment of other cell types, and skewing immune responses (8) . MMPs, including MMP9 and MMP1, aid the migration of immune cells through tissue, and have been demonstrated to promote the accumulation of MDSC (39) . IL-8 is a chemokine involved in recruitment and migration of neutrophils, T cells and basophils, and may act as an angiogenic factor (40) . Similarly, MCP-1 is highly chemotactic for monocytes, T cells, basophils and NK cells (40) . GRO may be involved in recruitment of neutrophils, may block differentiation of myeloid cells, and may induce production of immune suppressive cytokines by myeloid cells (41) . These molecules may thus contribute to further accumulation of inflammatory cells, may provide a feedback mechanism that leads to accumulation of further regulatory or suppressive cells, and may have far reaching effects in other organ systems when produced in circulation by elevated levels of MDSC. The chronic inflammatory state in patients with psoriasis may contribute to the increased risk of comorbidities. Notably, molecules including MMP9, MMP1 and IL-8 have been implicated in the pathogenesis of atheromas and cardiovascular disease (42) . As MDSCs accumulate in patients with acute coronary syndrome, this may indicate a potential association between these molecules, MDSCs, inflammation and cardiovascular disease (43) .
MDSCs have been recognized in patients with various types of cancer and autoimmune diseases. The results of the present study demonstrated that patients with psoriasis have significantly elevated levels of MDSCs in circulation. These cells are a heterogeneous population of immature myeloid cells that have immunoregulatory function, and may produce various factors that contribute to the chronic inflammatory state in these patients. As novel therapeutics and targets are discovered for the treatment of psoriasis, the present study identified an additional potential immune network that may be important in the pathogenesis of the disease. MDSCs produce various molecules. MDSCs were cultured in vitro in the absence of polyclonal activation, and culture supernatants were analyzed. Data are expressed as the mean ± standard deviation (n=7 patients). MMP9, MMP1, IL-8, GRO and MCP-1 were produced by unstimulated MDSCs. *** 2509±1685 pg/ml; ** 2094±1219 pg/ml; * 367±324 pg/ml. MDSCs, myeloid-derived suppressor cells; MMP, matrix metalloproteinase; IL, interleukin; GRO, growth-related oncogene; MCP, monocyte chemoattractant protein; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; TNF, tumor necrosis factor.
